Consensus LifeMD, Inc.

Stocks

LFMD

US53216B1044

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 00:00:00 09/07/2026 +04			5-day change	1st Jan Change
4.690 ^USD	-3.89%		+3.30%	+37.54%

06-22	LifeMD, Inc. And Antares Pharma, Inc. Launch Direct-To-Patient Self-Pay Program For XYOSTED (Testosterone Enanthate) Injection	CI
06-01	LifeMD, Inc. Announces Appointment of Umesh Sripad to Chief Technology Officer, Effective June 01, 2026	CI

Evolution of the Average Target: LifeMD, Inc.

Evolution of the Target Price: LifeMD, Inc.

Changes in Analyst Recommendations: LifeMD, Inc.

190565b4af85a977e0d59fefaecf.GyALrDceDdC7P2VP0zf73Q_GCfForApeSiIzvb2F2II.a2473w9NSYrzfDcqp2O2vGGceIY-nkEnGFJm1fbTgttwV2DIRV9Ype1RFg~22a29449e2e62654ffa95501adc83511

Analysts' recommendations: LifeMD, Inc.

03-16	Mizuho Upgrades LifeMD to Outperform From Neutral, Adjusts Price Target to $8 From $6	MT
01-16	Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly	RE
01-06	Sector Update: Health Care Stocks Decline Late Afternoon	MT
11-18	B. Riley Adjusts Price Target on LifeMD to $10 From $12, Maintains Buy Rating	MT
08/01/25	KeyBanc Cuts Price Target on LifeMD to $7.50 From $10, Keeps Overweight Rating	MT
04/12/24	Mizuho Initiates LifeMD at Neutral With $7 Price Target	MT
08/11/24	B. Riley Adjusts Price Target on LifeMD to $12 From $11, Maintains Buy Rating	MT
08/08/24	B. Riley Trims Price Target on LifeMD to $11 From $12, Maintains Buy Rating	MT
11/07/24	KeyBanc Adjusts Price Target on LifeMD to $10 From $12, Maintains Overweight Rating	MT
05/06/24	KeyBanc Initiates LifeMD at Overweight With $12 Price Target, Cites 'Strong Top & Bottom-Line Growth'	MT
09/05/24	Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	MT
23/04/24	BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating	MT
12/03/24	Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	MT
12/03/24	Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	MT
12/03/24	B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating	MT
11/01/24	HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating	MT
14/11/23	Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating	MT
09/11/23	HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating	MT
09/11/23	B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating	MT
02/10/23	Cantor Fitzerald Adjusts LifeMD Price Target to $8 From $7, Maintains Overweight Rating	MT
21/07/23	Cantor Fitzgerald Starts LifeMD at Overweight With $7 Price Target	MT
10/07/23	B. Riley Raises LifeMD's PT to $7 From $3.50 on Increased Conviction for Durable Growth, Enhanced EBITDA; Keeps Buy Rating	MT
03/07/23	HC Wainwright Initiates LifeMD With Buy Rating, $9 Price Target	MT
23/03/23	BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	MT
23/03/23	BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Objective/dr gap
LIFEMD, INC.		+110.55%
VEEVA SYSTEMS INC.		+29.98%
PRO MEDICUS LIMITED		-10.08%
SECTRA AB		+19.55%
HEARTFLOW, INC.		+41.49%
GENERATE BIOMEDICINES, INC.		+60.05%
OMNICELL, INC.		+35.83%
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	-	+45.87%
ARBUTUS BIOPHARMA CORPORATION	-	-1.42%
RAYSEARCH LABORATORIES AB	-	+44.86%
Average		+37.67%
Weighted average by Cap.		+20.84%